Sanjay Chanda - 05 Jan 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Signature
/s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda
Issuer symbol
ANTX
Transactions as of
05 Jan 2026
Net transactions value
-$9,332
Form type
4
Filing time
07 Jan 2026, 20:13:25 UTC
Previous filing
28 Feb 2025
Next filing
23 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chanda Sanjay Chief Development Officer C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK /s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda 07 Jan 2026 0001571820

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Sale $3,305 -3,295 -3.9% $1.00 81,779 05 Jan 2026 Direct F1, F2, F3
transaction ANTX Common Stock Sale $6,027 -5,956 -7.3% $1.01 75,823 06 Jan 2026 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.
F2 Includes (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
F3 Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025.